Genolution

Genolution CapEx/D&A

The CapEx to Depreciation Ratio of Genolution (225220.KQ) as of Nov 11, 2026 is 8.31. In the previous year, CapEx to Depreciation Ratio was 6.46 — a change of 28.60% (higher).

CapEx/D&A

8.31

YoY

28.60%

Last updated:

CapEx to Depreciation Ratio of Genolution is 2024 8.31 . CapEx to Depreciation Ratio of Genolution was 2023 6.46 . It decreases by 28.60% higher compared to the previous year.

The Genolution CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2017
7.49 KRW
Jan 1, 2018
13.23 KRW
Jan 1, 2019
12.24 KRW
Jan 1, 2020
22.26 KRW
Jan 1, 2021
6.38 KRW
Jan 1, 2022
25.35 KRW
Jan 1, 2023
6.46 KRW
Jan 1, 2024
8.31 KRW
The Genolution CapEx/D&A history
YEARCapEx/D&AYoY
8.31+28.60%
6.46-74.51%
25.35+297.30%
6.38-71.34%
22.26+81.96%
12.24-7.51%
13.23+76.57%
7.49+59.83%
4.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

CapEx to Depreciation Ratio of Genolution is 8.31 in 2024.

CapEx to Depreciation Ratio of Genolution changed from 6.46 to 8.31, representing a 28.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Genolution since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Genolution with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genolution

All Key Metrics — Genolution